Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVID‐19 pandemic

Larrouquère, Louis; Gabin, M. Ordobás; Poingt, Emmanuelle; Mouffak, Amelle; Hlavaty, Alex; Lepelley, Marion; Khouri, Charles; Bellier, Alexandre; Alexandre, Joachim; Bedouch, Pierrick; Bertoletti, Laurent; Bordet, Régis; Bouhanick, Béatrice; Jonville‐Béra, Annie‐Pierre; Laporte, Silvy; Jeunne, Claire Le; Létinier, Louis; Micallef, Joëlle; Naudet, Florian; Roustit, Matthieu; Molimard, Mathiéu; Richard, Vincent; Cracowski, Jean‐Luc

doi:10.1111/fcp.12564

Cited by 27 publications

(21 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…She remained asymptomatic without interrupting biological therapy. Overall, these results do not support a higher incidence of SARS-CoV-2 infection in this population and supports the approach of maintaining chronic rheumatological treatments [37] and adherence to infection control measures, thus avoiding a relapse of rheumatic disease without increasing the risk of COVID-19.…”

Section: Are Patients With Autoimmune Rheumatic Disease a Population contrasting

confidence: 55%

Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review

Grange

Guilpain

Truchetet³

et al. 2020

Therapies

Self Cite

View full text Add to dashboard Cite

, the COVID-19 pandemic has become a major public health problem. To date, there is no evidence of a higher incidence of COVID in patients with autoimmune rheumatic diseases and we support the approach of maintaining chronic rheumatological treatments. However, once infected there is a small but significant increased risk of mortality. Among the different treatments, NSAIDs are associated with higher rates of complications, but data for other drugs are conflicting or incomplete. The use of certain drugs for autoimmune inflammatory rheumatisms appears to be a potentially interesting options for the treatment. The rationale for their use is based on the immune system runaway and the secretion of proinflammatory cytokines (Il1, IL6, TNF␣) in severe forms of the disease. Notably, patients on chloroquine or hydroxychloroquine as a treatment for their autoimmune rheumatic disease are not protected from COVID-19.

show abstract

Section: Are Patients With Autoimmune Rheumatic Disease a Population contrasting

confidence: 55%

Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review

Grange

Guilpain

Truchetet³

et al. 2020

Therapies

Self Cite

View full text Add to dashboard Cite

show abstract

“…Since these reports are not peer-reviewed, they cannot be considered as validated information, and thus should not guide clinical practice [56]. In parallel, we have recorded a growing request for reliable information on the efficacy and safety of hydroxychloroquine from the population [57].…”

Section: The Impact Of Massive Use Of Hydroxychloroquine On the Condumentioning

confidence: 99%

Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence

et al. 2020

View full text Add to dashboard Cite

Chloroquine and hydroxychloroquine are drugs that have shown in vitro activity on the replication of certain coronaviruses. In the context of the SARS-Cov-2 epidemic, the virus responsible for the novel coronavirus disease (COVID-19), these two drugs have been proposed as possible treatments. The results of the first clinical studies evaluating the effect of hydroxychloroquine do not support any efficacy of this drug in patients with COVID-19, due to major methodological weaknesses. Yet, these preliminary studies have aroused considerable media interest, raising fears of massive and uncontrolled use. In the absence of evidence of clinical benefits, the main risk is of exposing patients unnecessarily to the well-known adverse

show abstract

“…On March 16, 2020, the French Society of Pharmacology and Therapeutics has launched a national FAQs website at https://sfpt-fr.org/covid19, focused on the proper use of drugs during the COVID-19 pandemic [4]. The French addictovigilance network has joined the scientific council and has participated to document the responses to each question related to addictovigilance.…”

Section: Contribution To Covid-19 Faqs Of the French Society Of Pharmmentioning

confidence: 99%

“…In the context of COVID-19 epidemic, the French regional pharmacovigilance centres network ensured this mission [1], with an assessment maintained in its continuity, based on a pharmacological and medical characterization of cases, shared with a population-based approach integrating pharmacoepidemiological methods when possible, contributing to optimizing the level of evidence. Sharing and collaboration, both within and beyond the French Pharmacology and Therapeutics scientific community, was integral within these special weeks and beyond (see frequently asked questions [FAQ] at https://sfpt-fr.org/covid19) [2][3][4].…”

Section: Introductionmentioning

confidence: 99%

Addictovigilance contribution during COVID-19 epidemic and lockdown in France

Lapeyre‐Mestre¹,

Boucher²,

Daveluy

et al. 2020

Therapies

Self Cite

View full text Add to dashboard Cite

show abstract

Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVID‐19 pandemic

Abstract: These authors contributed equally to the work.

Cited by 27 publications

References 10 publications

Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review

Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review

Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence

Addictovigilance contribution during COVID-19 epidemic and lockdown in France

Contact Info

Product

Resources

About